Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...